Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CTIF antisense RNA 1 (CTIF-AS1)
- Target
- CTIF-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
CTIF antisense RNA 1 (CTIF-AS1) is a long non-coding RNA (lncRNA) transcribed from the DNA strand opposite to *CTIF* (Cap Binding Complex Dependent Translation Initiation Factor) gene. Like other antisense lncRNAs, CTIF-AS1 is presumed to function in the regulation of its sense gene at the transcriptional, epigenetic, or post-transcriptional level, possibly affecting gene expression through RNA-RNA and RNA-protein interactions, epigenetic modification, or modulation of mRNA stability. While antisense RNAs can act as oncogenes or tumor suppressors and serve as disease biomarkers, there is limited functional or clinical information specifically about CTIF-AS1.
02
Mechanism of action
Not applicable (no drugs known to directly target CTIF-AS1)
03
Biological functions
Regulation of gene expression, especially affecting its sense coding gene (in this case, likely *CTIF*)Epigenetic regulation (potentially via DNA methylation and histone modification, as with other antisense lncRNAs)Post-transcriptional regulation
04
Disease associations
Other (while antisense lncRNAs are implicated in cancer and other diseases, there are no specific reports linking CTIF-AS1 directly to a particular disease)
05
Biomarkers
Antisense lncRNAs in general are emerging as potential biomarkers in cancer, but CTIF-AS1-specific biomarker roles are not reported
Beyond the preview
Go deeper on CTIF antisense RNA 1 (CTIF-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTIF antisense RNA 1 (CTIF-AS1).